Keywords: strong, ph, iii, copd, data, nycomed, daxas

Strong Ph III COPD data for Nycomed's Daxas

Article | 10 November 2008

Print This

Swiss drugmaker Nycomed has reported encouraging results from a preliminary analysis of four Phase III trials of Daxas (roflumilast) in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in